APLS Historical PE Ratio Notes

— Apellis Pharmaceuticals (APLS) is a biopharmaceutical company focused on developing therapies for rare, chronic, and debilitating diseases, mainly through the inhibition of the complement system, a part of the immune response. Its most notable product, SYFOVRE, is the first and only approved treatment for geographic atrophy (GA), an advanced form of age-related macular degeneration, as well as EMPAVELI for paroxysmal nocturnal hemoglobinuria (PNH). As you review APLS historical PE ratio, keep in mind that drug development companies like Apellis often have volatile, sometimes negative earnings due to intensive, long-term R&D investment without immediate revenue streams. Consequently, PE ratios may be extremely high or undefined during periods of net losses, only normalizing once meaningful product sales begin. Fluctuations in the PE ratio often correspond to clinical milestones, FDA approvals, or commercial launches, as these events dramatically shift market sentiment and earnings expectations. Understanding Apellis's history of product launches and pipeline progress will be crucial context as you examine historical price, earnings, and PE ratio data, since these milestones tend to drive investor sentiment and valuation far more than steady earnings growth typical of more mature industries.

On this page we presented the APLS Historical PE Ratio information for Apellis Pharmaceuticals' stock. The average APLS historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is 27.8. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average APLS historical PE based on this TTM earnings result method is 92.4. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this APLS historical PE result, against the recent PE: when this page was posted on 5/14/2026, the most recent closing price for APLS had been 41.03, and the most recent quarterly earnings result, annualized, was 0.6. Meanwhile, the most recent TTM earnings summed to 1.02. From these numbers, we calculate the recent APLS PE on 5/14/2026 based on annualized quarterly EPS was 68.4. Based on APLS's history, that recent PE is elevated relative to the historical average, with the recent PE 146.0% higher than the historical average PE across our data set for Apellis Pharmaceuticals. Looking at the recent APLS PE on 5/14/2026 based on TTM EPS, we calculate the ratio at 40.2. Based on APLS's history, that recent PE is low relative to the historical average, with the recent PE 56.5% lower than the average PE across our Apellis Pharmaceuticals data set with TTM EPS used in the calculation at each period.

For self directed investors doing their due diligence on APLS or any other given stock, valuation analysis for APLS can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Apellis Pharmaceuticals PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for APLS. Thanks for visiting, and the next time you need to research APLS Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.